Wegovy, Novo Nordisk A/S’s blockbuster weight-loss drug, improved heart failure symptoms in patients with diabetes in the most recent major trial to support the drug’s use to treat obesity-related health conditions.
Patients who took Wegovy reported less fatigue, less swelling of their legs, less shortness of breath and were capable of walk further in six minutes than those that received a placebo, researchers said reported on Saturday within the New England Journal of Medicine. The Wegovy patients also reported less serious medical problems.
The study is the most recent in a series of huge studies Novo is conducting to prove that Wegovy can assist individuals with a spread of conditions, from knee arthritis to Cardiovascular system Illness. The Danish drugmaker is using the findings to bolster its argument that cost-conscious insurers should cover the drug, whose list price within the U.S. is about $1,350 a month.
The heart failure study published Saturday is an element of two studies that examined heart failure with preserved ejection fraction Condition This happens when the lower chamber of the guts pumps less blood than the body needs. According to 1 study, it affects about 3 million people within the United States and as much as 32 million people world wide, with an annual mortality rate of about 15% review published last 12 months within the medical journal JAMA.
Novo reported early results from the guts failure trial when it reported fourth-quarter ends in January. The study on individuals with diabetes follows on from the same study published last 12 months from patients with heart failure who had obesity but not diabetes. The company submitted the outcomes of each trials to U.S. and European regulators in January.
— With assistance from Madison Muller
